Progress in refining the clinical management of cancer of unknown primary in the molecular era

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Nature Reviews Clinical Oncology

• Publication date

  2020-04-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41571-020-0359-1PMID 32350398
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of site-specific therapy for cancers of unknown of primary: A meta-analysis.

  2020cited by this paper
• Exploring the biological hallmarks of cancer of unknown primary: where do we stand today?

  2020cited by this paper
• Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

  2020cited by this paper
• New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?

  2020cited by this paper
• Paraneoplastic syndromes in cancers of unknown primary: An unknown field for oncologists.

  2019cited by this paper
• Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome

  2019cited by this paper
• Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal‐Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP‐mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature

  2019cited by this paper
• Identification of cancer driver genes based on nucleotide context

  2019cited by this paper
• A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)

  2019cited by this paper
• Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care.

  2019cited by this paper
• Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.

  2019cited by this paper
• Precision medicine for metastatic colorectal cancer: an evolving era

  2019cited by this paper
• Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials

  2019cited by this paper
• Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma.

  2019cited by this paper
• Comprehensive management of HPV‐related squamous cell carcinoma of the head and neck of unknown primary

  2019cited by this paper
• The currently declining incidence of cancer of unknown primary.

  2019cited by this paper
• Clinical impact of tissue of origin testing and mutation profiling in the Solving Unknown Primary Cancer (SUPER) national prospective study: Experience of the first two years.

  2019cited by this paper
• Familial cancer of unknown primary

  2019cited by this paper
• Cancer of unknown primary: Incidence rates, risk factors and survival among adolescents and young adults

  2019cited by this paper
• A new entity of abdominal squamous cell carcinoma of unknown primary

  2019cited by this paper
• Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

  2019cited by this paper
• Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?

  2019cited by this paper
• Renal Cell Carcinoma Presenting as Carcinoma of Unknown Primary Site: Recognition of a Treatable Patient Subset

  2018cited by this paper
• The current evidence for a biomarker-based approach in cancer of unknown primary.

  2018cited by this paper
• A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

  2018cited by this paper
• Precision Medicine in Non-Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation.

  2018cited by this paper
• TRKA expression and NTRK1 gene copy number across solid tumours

  2018cited by this paper
• Genetic characterisation of molecular targets in carcinoma of unknown primary

  2018cited by this paper
• Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.

  2018cited by this paper
• Survival outcome differences based on treatments used and knowledge of the primary tumour site for patients with cancer of unknown and known primary in Ontario.

  2018cited by this paper
• Resolving diagnostic uncertainty in bone-predominant metastases in cancer of unknown primary (CUP) using the 92-gene assay.

  2018cited by this paper
• Cancer of unknown primary—Epidemiological trends and relevance of comprehensive genomic profiling

  2018cited by this paper
• Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the ‘U’ out of ‘CUP’

  2018cited by this paper
• Emerging role of precision medicine in biliary tract cancers

  2018cited by this paper
• OncoKB: A Precision Oncology Knowledge Base.

  2017cited by this paper
• Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.

  2017cited by this paper
• SEOM clinical guideline on unknown primary cancer (2017)

  2017cited by this paper
• Clinical and molecular characterization of patients with cancer of unknown primary in the modern era

  2017cited by this paper
• Cancers of unknown primary diagnosed during hospitalization: a population-based study

  2017cited by this paper
• Circulating and disseminated tumor cells: harbingers or initiators of metastasis?

  2017cited by this paper
• Location of metastases in cancer of unknown primary are not random and signal familial clustering

  2016cited by this paper
• Age-Dependent Metastatic Spread and Survival: Cancer of Unknown Primary as a Model

  2016cited by this paper
• Molecular driver alterations and their clinical relevance in cancer of unknown primary site

  2016cited by this paper
• Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.

  2016cited by this paper
• Germline genetics of cancer of unknown primary (CUP) and its specific subtypes

  2016cited by this paper
• Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.

  2015cited by this paper
• Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.

  2015cited by this paper
• Successful Control of Carcinoma of Unknown Primary with Axitinib, a Novel Molecular-Targeted Agent: A Case Report

  2015cited by this paper
• The migration ability of stem cells can explain the existence of cancer of unknown primary site. Rethinking metastasis

  2015cited by this paper
• Development and validation of a gene expression tumour classifier for cancer of unknown primary

  2015cited by this paper
• Cancers of unknown primary origin (CUP) are characterized by chromosomal instability (CIN) compared to metastasis of know origin

  2015cited by this paper
• Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.

  2015cited by this paper
• Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care

  2014cited by this paper
• Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin.

  2014cited by this paper
• Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group

  2014cited by this paper
• Descriptive epidemiology of cancer of unknown primary site in Scotland, 1961-2010.

  2014cited by this paper
• Development of a histology-guided gene expression tumor classifier for cancer of unknown primary (CUP).

  2014cited by this paper
• Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases

  2014cited by this paper
• Insights into the epithelial mesenchymal transition phenotype in cancer of unknown primary from a global microRNA profiling study

  2014cited by this paper
• Carcinoma of Unknown Primary (CUP)

  2014cited by this paper
• Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.

  2013cited by this paper
• Observational study of real world clinical performance of microrna molecular profiling for cancer of unknown primary (CUP).

  2013cited by this paper
• Removing the unknown from the carcinoma of unknown primary.

  2013cited by this paper
• Origins of metastatic traits.

  2013cited by this paper
• Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP)

  2013cited by this paper
• Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset

  2013cited by this paper
• Cancer of unknown primary: a population-based analysis of temporal change and socioeconomic disparities

  2013cited by this paper
• Mutational landscape and significance across 12 major cancer types

  2013cited by this paper
• Papillary Renal Cell Carcinoma Presented With Supraclavicular Lymph Node Metastasis Without Renal Primary Lesion

  2013cited by this paper
• Massively‐parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary

  2013cited by this paper
• Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.

  2013cited by this paper
• Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks

  2013cited by this paper
• Time trends in incidence, causes of death, and survival of cancer of unknown primary in Sweden

  2012cited by this paper
• Cancer of unknown primary (CUP): does cause of death and family history implicate hidden phenotypically changed primaries?

  2012cited by this paper
• Survival in cancer of unknown primary site: population-based analysis by site and histology.

  2012cited by this paper
• Clinical and Biological Implications of the Tumor Microenvironment

  2012cited by this paper
• Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases.

  2012cited by this paper
• Identifying the Primary Site Using Gene Expression Profiling in Patients with Carcinoma of an Unknown Primary (CUP): A Feasibility Study from the GEFCAPI

  2012cited by this paper
• Profiling immunohistochemical expression of NOTCH1–3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary

  2012cited by this paper
• Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility.

  2012cited by this paper
• Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2012cited by this paper
• Cancer of unknown primary site.

  2012cited by this paper
• 1450 POSTER Immunohistochemical Profiling of Signalling Pathways in Cancer of Unknown Primary (CUP)

  2011cited by this paper
• Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

  2011cited by this paper
• Prospective Gene Signature Study Using microRNA to Identify the Tissue of Origin in Patients with Carcinoma of Unknown Primary

  2011cited by this paper
• A DNA methylation fingerprint of 1628 human samples.

  2011cited by this paper
• MicroRNA profiling for the identification of cancers with unknown primary tissue‐of‐origin

  2011cited by this paper
• MET mutations in cancers of unknown primary origin (CUPs)

  2011cited by this paper
• Hypoxia-related protein expression and its clinicopathologic implication in carcinoma of unknown primary

  2011cited by this paper
• Molecular tumor profiling (MTP) in cancer of unknown primary site (CUP): A complement to standard pathologic diagnosis.

  2011cited by this paper
• Hybrid model integrating immunohistochemistry and expression profiling for the classification of carcinomas of unknown primary site.

  2010cited by this paper
• Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site

  2010cited by this paper
• Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site

  2010cited by this paper
• Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test

  2010cited by this paper
• Carcinoma of unknown primary (CUP).

  2009cited by this paper
• Phase II Trial of Capecitabine and Oxaliplatin in Patients with Adeno- and Undifferentiated Carcinoma of Unknown Primary

  2009cited by this paper
• Cancer patients without a known primary: Incidence and survival trends in Sweden 1960–2007

  2009cited by this paper
• Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.

  2009cited by this paper
• Implementation of a novel microarray‐based diagnostic test for cancer of unknown primary

  2009cited by this paper

• Deep learning for malignancy and tumor origin prediction using cytology or histopathology whole slide images

  2026cites this paper
• Is It Time to Retire the Unified Cancer of Unknown Primary Concept in the Precision Oncology Era?

  2026cites this paper
• Mortality Trends in Cancer of Unknown Primary Site in Serbia, 1990–2024: A Joinpoint Regression and Age–Period–Cohort Analysis

  2026cites this paper
• Analysis of cancer stem cell mechanism and immune profiling in breast cancer of unknown primary.

  2026cites this paper
• Outcomes of HPV+ Oropharyngeal Carcinoma of Unknown Primary Following Transoral Robotic Surgery

  2025cites this paper
• Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment

  2025cites this paper
• Dynamic hypergraph representation for bone metastasis analysis

  2025cites this paper
• Cancer of unknown primary: Diagnosis, treatment and technological advances.

  2025cites this paper
• The application of tumor origin genetic testing in differential diagnosis of breast metaplastic carcinoma

  2025cites this paper
• Mutational landscape and DNA methylation-based classification of squamous cell carcinoma and urothelial carcinoma

  2025cites this paper
• Cancer of Unknown Primary Site.

  2025cites this paper
• Molecularly directed therapy in cancers of unknown primary: A systematic review and meta-analysis.

  2025cites this paper
• Skeletal Muscle Density as a Predictor of Prognosis and Physical Reserve in Patients with Cancer of Unknown Primary

  2025cites this paper
• Advancements in Diagnostics and Therapeutics for Cancer of Unknown Primary in the Era of Precision Medicine

  2025cites this paper
• The complex clinical challenges of secondary ovarian tumors and cancer of unknown primary: diagnostic and therapeutic considerations

  2025cites this paper
• Clinical characteristics and survival analysis of cancer of unknown primary

  2025cites this paper
• Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysis

  2025cites this paper
• Large language models enable tumor-type classification and localization of cancers of unknown primary from genomic data

  2025cites this paper
• Clinical efficacy of immune checkpoint inhibitors for cancer of unknown primary: a multi-center retrospective study

  2025cites this paper
• Tissue of origin prediction for cancer of unknown primary using a targeted methylation sequencing panel

  2024influential citation
• Diagnosis progress of carcinoma of unknown primary

  2024cites this paper
• A machine learning-based method for feature reduction of methylation data for the classification of cancer tissue origin

  2024cites this paper
• New clinical trials in CUP and a novel paradigm in cancer classification

  2024cites this paper
• A new paradigm for cytology-based artificial intelligence-assisted prediction for cancers of unknown primary origins

  2024cites this paper
• Next-generation chemotherapy treatments based on black hole algorithms: From cancer remission to chronic disease management

  2024cites this paper
• A deep learning method for predicting the origins of cervical lymph node metastatic cancer on digital pathological images

  2024cites this paper
• Metastatic renal cell carcinoma with occult primary: a multicenter prospective cohort

  2024cites this paper
• Application of Transcriptome-Based Gene Set Featurization for Machine Learning Model to Predict the Origin of Metastatic Cancer

  2024cites this paper
• Image-based deep learning model using DNA methylation data predicts the origin of cancer of unknown primary

  2024influential citation
• Predicting tumour origin with cytology-based deep learning: hype or hope?

  2024influential citation
• Prediction of tumor origin in cancers of unknown primary origin with cytology-based deep learning

  2024influential citation
• Retrospective analysis of clinical characteristics and outcomes of patients with carcinoma of unknown primary from three tertiary centers in Australia

  2024cites this paper
• New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges

  2024cites this paper
• Automatic origin prediction of liver metastases via hierarchical artificial-intelligence system trained on multiphasic CT data: a retrospective, multicentre study

  2024cites this paper
• Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity score-matched cohorts of cancer of unknown primary treatment

  2023cites this paper
• The diagnosis and treatment for a patient with cancer of unknown primary: A case report

  2023cites this paper
• Mutated axon guidance gene PLXNB2 sustains growth and invasiveness of stem cells isolated from cancers of unknown primary

  2023cites this paper
• From Biology to Diagnosis and Treatment: The Ariadne’s Thread in Cancer of Unknown Primary

  2023cites this paper
• Analysis of the Impacts of Consuming Red and Processed Meat on Colorectal Cancer and the role of Machine Learning in Clinical Diagnostics

  2023cites this paper
• HiTAIC: hierarchical tumor artificial intelligence classifier traces tissue of origin and tumor type in primary and metastasized tumors using DNA methylation

  2023cites this paper
• Six-year experience of Australia’s first dedicated cancer of unknown primary clinic

  2023cites this paper
• Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics

  2023cites this paper
• Long-read transcriptome landscapes of primary and metastatic liver cancers at transcript resolution

  2023cites this paper
• Can Precision Oncology Benefit Patients With Cancers of Unknown Primary?

  2023cites this paper
• Artificial Intelligence-based Risk Stratification, Accurate Diagnosis and Treatment Prediction in Gynecologic Oncology.

  2023cites this paper
• Identifying primary tumor site of origin for liver metastases via a combination of handcrafted and deep learning features

  2023cites this paper
• Intraoperative Flow Cytometry Upon and Beyond the Cell Cycle: A Case Study of the Characterization of a Bone Metastasis

  2023cites this paper
• Machine learning for pan-cancer classification based on RNA sequencing data

  2023cites this paper
• The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review

  2023cites this paper
• Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China

  2023cites this paper
• Cancer of unknown primary—state of the art

  2023cites this paper
• Clinicopathological, molecular and prognostic characteristics of cancer of unknown primary in China: An analysis of 1420 cases

  2022cites this paper
• An accurate prediction of the origin for bone metastatic cancer using deep learning on digital pathological images

  2022cites this paper
• Cancer epigenetics in clinical practice

  2022cites this paper
• Epidemiology of Undifferentiated Carcinomas

  2022cites this paper
• Clinicopathological Features and Clinical Outcomes of Metastatic Adenocarcinoma of Unknown Primary: A Single Center Experience

  2022cites this paper
• Case Report: Successful Immunotherapy Improved the Prognosis of the Unfavorable Subset of Cancer of Unknown Primary

  2022cites this paper
• Validation of a Transcriptome-Based Assay for Classifying Cancers of Unknown Primary Origin

  2022cites this paper
• Refinement of computational identification of somatic copy number alterations using DNA methylation microarrays illustrated in cancers of unknown primary

  2022cites this paper
• A Machine Learning Method to Trace Cancer Primary Lesion Using Microarray-Based Gene Expression Data

  2022cites this paper
• Identifying the origination of liver metastasis using a hand-crafted computational pathology approach

  2022cites this paper
• SEOM—GECOD clinical guideline for unknown primary cancer (2021)

  2022cites this paper
• Clinical validation of a 90-gene expression test for tumor tissue of origin diagnosis: a large-scale multicenter study of 1417 patients

  2022cites this paper
• Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis

  2022cites this paper
• An overview of artificial intelligence in oncology

  2022cites this paper
• Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better

  2022cites this paper
• Molekulare Diagnostik und „liquid biopsies“ bei Karzinomen unklarer Primärlokalisation

  2021influential citation
• THE ISSUE OF TUMOR MARKERS AND THEIR INTERPRETATION

  2021cites this paper
• Site-specific chemotherapy based on gene expression profiling versus empirical chemotherapy for people with cancer of unknown primary site

  2021cites this paper
• Identification of tissue of origin and guided therapeutic applications in cancers of unknown primary using deep learning and RNA sequencing (TransCUPtomics).

  2021cites this paper
• Response to “The need for validation of MI GPSai in patients with CUP: Comment on: “Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type” by J Abraham et al.“

  2021cites this paper
• Expression of Glycolysis-Related Proteins in Cancer of Unknown Primary Origin

  2021cites this paper
• Meat consumption and cancer of unknown primary (CUP) risk: results from The Netherlands cohort study on diet and cancer

  2021cites this paper
• Axillary Nodal Metastases from Carcinoma of Unknown Primary (CUPAx): Role of Contrast-Enhanced Spectral Mammography (CESM) in Detecting Occult Breast Cancer

  2021cites this paper
• Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary

  2021cites this paper
• Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition

  2021cites this paper
• Comparative genomic characterization of melanoma of known and unknown primary

  2021cites this paper
• Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP)

  2021cites this paper
• The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry.

  2021cites this paper
• 90-Gene Expression Profiling for Tissue Origin Diagnosis of Cancer of Unknown Primary

  2021cites this paper
• Gene Expression Profiling for Differential Diagnosis of Liver Metastases: A Multicenter, Retrospective Cohort Study

  2021cites this paper
• Keep your eyes peeled for long noncoding RNAs: Explaining their boundless role in cancer metastasis, drug resistance, and clinical application.

  2021cites this paper
• Real-world data analysis of patients with cancer of unknown primary

  2021cites this paper
• Stem-like cells from Cancer of Unknown Primary are endowed with distinctive hypermetastatic properties and unveil liability to MEK inhibition

  2020influential citation
• AI-based pathology predicts origins for cancers of unknown primary

  2020cites this paper
• The diagnostic challenges of patients with carcinoma of unknown primary

  2020cites this paper
• Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.

  2020cites this paper
• The spectrum of pathological diagnoses in non-sentinel axillary lymph node biopsy: A single institution's experience.

  2020cites this paper
• The management of patients with cancer of unknown primary in middle-income countries: an ESO-AROME survey.

  2020cites this paper
• The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary✰: Molecular profiling of metastatic cancer of unknown primary.

  2020cites this paper
• Insights from the genetic and transcriptional characterization of a cancer of unknown primary (CUP)

  2020cites this paper
• What can we learn from cancer of unknown primary in canine oncology?

  2020cites this paper